Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have been informed by "Etoro" that they cannot deal Portage Biotech (PRTG) shares on NASDAQ as there is no specific bid and ask at the current volumes. As has been said before, they are mainly an over the counter share with matched bargains so is something Etoro are unable to do (at present) ... that is, until they issue more stock and become a fully-fledged share like Biohaven (BHVN) has become, with high daily liquidity.
Most of the recorded transactions so far for PRTG on NASDAQ are for parcels of 100 shares, but there is no indication of whether they are buys or sells.
SALV hopefully will re-list as soon as is practical. Rumor has it that an unlisted company is lined up, just a waiting game really.
Yes SALV has got value as pointed out of approx. 30p a share.
Not quite on Nasdaq topic but can someone clear my confusion please? I sold my Portage shares some time ago, but I also bought about 1800 SalvaRx shares . What happens to them.? Do they have any value at all? Would be grateful for help.
Many thanks
This shell has to be worth around 30p a share in Portage right now. Got 50k of these and very impatient now..lol
I am exploring the possibility of being able to deal in PRTG on NASDAQ via the "Etoro" trading platform with low expenses and easy transfer of proceeds to UK ...
Currently, "Etoro" doesn't recognise the newly listed PRTG ticker on NASDAQ, but shouldn't be long now before they update their system.
Then it will be possible to buy and sell PRTG, providing the spread isn't too large.
Whatever happens, you must download the W8-BEN form and submit it, to be able to realise proceeds to UK exempt from higher US tax charges.
No that quote was actually $36 to buy $23 to sell and only up to 100 shares. HL and AJ bell.
It’s still so hard to sell our Portage shares from Salvarx. Those shares which are still on CSE. Tried to sell 1k. No luck. 500. Might take several days. 250 with a spread of $33 / $24. Crazy. Then they got back and said they could only quote for 100. Anybody else tried to sell ?
Portage Biotech opened at $37.50 on NASDAQ
https://www.nasdaq.com/market-activity/stocks/prtg/real-time
At current price of Portage and at last known number of shares the value is around 30p for each Salv share. There was only around £50k in cash so I imagine that’s gone. Though they did say they would only pay the BOD a token £10k a year.
What cash other than the Portage Holding did the company end up with. Cant remember the number of shares in issue to try and work out value. Chuffed with Portage and hanging on to them.
Let’s not forget that the value of Salv rises inline with Portage. This shell is currently worth $17m and will be a lot more next week. Let’s see whether we get Portage shares or if an asset is on its way. Whatever happens you can guarantee that with a few people holding massive % it will be in all of our interests.
After the public holiday on Monday (Canadian National Flag Day) th CSE markets have reopened with Portage Biotech nudging US$28 ...
More to come after the NASDAQ announcement ... expect it to fly once listed on a main market.
FFWD who has Jim Mellon involved is also rising on AIM, it has a small percentage in Portage amongst other promising acquisitions it has made (in the gaming and medical cannabis fields).
.... In the long term this is about turning cancer into a chronic disease.”
So, 5 years on, SALV is no longer listed on AIM, but the science was sold to Portage Biotech, who are now seeking a listing on NASDAQ.
What is there to say that SALV will be resurrected as a vehicle for Portage Biotech to be also listed on the main London market at many times the value it was last seen ... Jim Mellon has a history of engineering this sort of thing, as can be seen from what happened with 3Legs Resources.
Interesting to see how far we have come from the RTO of 3Legs Resources to obtain a listing on AIM:
This is what Wiseacre posted on ADVFN 21/03/2016
wiseacre: An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group. SalvaRX has been set up with backing from Jim Mellon, the Isle of Man-based investor, as an incubator for early-stage cancer drug developers. More On this topic Call for tighter controls for drug trials Anjana Ahuja Ditching your birth identity Immune cell breakthrough in cancer fight Bioelectrics industry is one to watch IN Pharmaceuticals Valeant is the latest troubled roll-up to unravel Witty’s tenure at GSK divides opinion Analysts bullish as Valeant struggled Witty defends GSK strategy to the end Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours. SalvaRX’s chief executive, Ian Walters, and its chief scientific officer, Robert Kramer, were both senior members of the team that put BMS at the forefront of a new class of cancer drugs called immunotherapies. These medicines, which harness the immune system to destroy tumours, are widely seen as the most important cancer breakthrough for decades and have been tipped to generate tens of billions of dollars in annual sales for the pharma industry. SalvaRX will scour academia and the biotech sector for novel immunotherapies and deploy capital and expertise to develop them. The company’s shares are due to begin trading on London’s junior Aim market on Tuesday after a reverse takeover of 3Legs Resources, a shell company backed by Mr Mellon which was previously engaged in a failed search for shale gas in Poland. Mr Mellon, whose wealth was estimated at £850m in last year’s Sunday Times rich list, made his fortune in mining but also invests in life sciences. SalvaRX raised just under £2m in a share placement as part of its reversal into the Aim shell and Dr Walters said the company planned a more substantial fundraising with institutional investors in due course. See Today's FT: The company owns 60 per cent of iOx with the rest held by Oxford university and Ludwig Cancer Research, a global network of leading cancer scientists. IOx’s so-called iNKT agonist drugs have shown promise in animals and Dr Walters said the first clinical trials in humans would start soon, financed by Oxford. Dr Walters acknowledged that cancer immunotherapy had become a crowded field but insisted there was still plenty of untapped science — especially in Europe — beyond the “checkpoint inhibitors” that have attracted most investment so far. “Eighty-five per cent of the industry is focusing on checkpoints and antibodies. We are focusing on the other areas where there is a lot of white space,” he said. “The science is advancing exponentially so there is so much more to come.....
PORTAGE BIOTECH PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND ANNOUNCES NASDAQ LISTING APPROVAL
NewsfileFEB 11, 2021 08:00 AM EST
-- Company to advance three clinical-stage programs in pipeline --
-- Portage has received approval and is preparing for NASDAQ listing --
Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") today announced its 2021 research and development goals, including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ Capital Market ("NASDAQ") to list its common shares on the NASDAQ exchange, and expects to commence trading February 25, 2021 under the symbol "PRTG."